Search results for " treatment regulations"

Article Emerging Therapies Test Existing Bioanalytical Methods
Drug developers must understand the complex bioanalytical assays for cell- and gene-therapy drug development programs and ensure that partners have the specialized expertise needed for complex thera…

Article Avoiding Investigational Failures and Discrepancies
Avoiding Investigational Failures and Discrepancies Investigational failures and discrepancies can be avoided through the proper execution and documentation of investigations. By Walt Murray,…

Article Ensuring the Biological Integrity of Raw Materials
By Catherine Shaffer Contamination with microbes, mycoplasma, viruses, and other adventitious agents can be a significant problem in biopharmaceutical manufacturing. Although contamination can o…

Article EMA Collaborates with HTA Assessment Networks
High technology assessments are having an impact on biosimilars development in Europe. Gaining access to Europe’s pharmaceutical markets has become a multi-stage operation. The licensing of a…

Article Moving Biosimilars Forward in a Hesitant Market
The biosimilars landscape is growing as market factors, such as pricing pressure, advanced bioprocessing and analytical technologies, and upcoming patent expirations for innovator biologics dr…

Article Expanding the Emerging Therapeutic Horizon
Despite the successes that have already been achieved with emerging therapy development and manufacturing, companies are still facing numerous challenges. Aspects such as demand for accelerate…

Article A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU Legal experts in biopharmaceutical patent law shed some light on trends and recent news. By Agnes Shanley …

Article Biosimilar Quality Requirements
This article reviews FDA’s recent efforts to streamline the biosimilar approval process and address quality concerns with the publication of new guidelines that suggest resources to aid in the biosi…

Article Moving PAT from Concept to Reality
The learning curve for process analytical technology has slowed widespread adoption. By Cynthia A. Challener alexlmx a- Stock.Adobe.com Process analytical technology (P…

Article Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
The year ahead is expected to be marked by increased biosimilar development, lower drug prices, and better quality drugs. The global biopharmaceuticals market was valued at $162 billion in 2014 a…

Previous PageNext Page